From innovation to clinical use: market introduction of AdhFix and FRAP
| Reference number | |
| Coordinator | Biomedical Bonding AB |
| Funding from Vinnova | SEK 200 000 |
| Project duration | May 2026 - December 2026 |
| Status | Ongoing |
| Venture | Medtech4Health: Competence Enhancement in SME |
| Call | Medtech4Health: Competence Enhancement in Small Businesses, spring 2026 |
Purpose and goal
The project focuses on developing a commercialization strategy for Europe through analysis of market potential, pricing, competition and reimbursement systems. The goal is to identify priority launch markets and establish strategic distribution partners.
Expected effects and result
The project is expected to deliver: • a complete commercialization strategy • prioritized markets for launch • established contacts with distributors • a market-adapted pricing model This creates the conditions for international market introduction of AdhFix and later launch of FRAP.
Planned approach and implementation
An external expert will contribute with experience in commercialization and market introduction of medical devices and establishment of international distribution structures. The project will provide strategic business expertise that strengthens the organisation´s ability to introduce AdhFix and FRAP to the European market.